Entries by cpdcit

Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments

HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation – JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital and FACIT (Fight Against […]

FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics

Image-guided medicines for hard to treat cancers built using next generation medical isotopes TORONTO, ON (December 16, 2015) – FACIT and Fusion Pharmaceuticals (“Fusion”) announced today an investment to support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer. Fusion’s drug candidate leverages the potent cell-killing potential of alpha particle-emitting medical isotopes, with […]

Fusion Pharmaceuticals to Present at the Biotech Showcase 2016 Conference on January 11th, 2016

HAMILTON, ONT. — 05/01/16 — Fusion Pharmaceuticals, Inc. (“Fusion”), a life sciences company focused on developing novel drugs for the targeted delivery of high-energy alpha-emitting radioactive isotopes to treat solid cancers, announced today that it will be featured as a presenting company at The Biotech Showcase™ 2016 Conference taking place from January 11-13, 2016. The […]